# National Cancer Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/national-cancer-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 66.4 |
| Citations | 1,378,293 |
| City | Plainview |
| Country | US |
| Description | National Cancer Center is a research organisation in Plainview, US. OpenAlex records 16,759 works and 1,378,293 citations for it. 5,427 researchers list it as their most recent affiliation. |
| Homepage | http://www.nationalcancercenter.org/ |
| OpenAlex ID | https://openalex.org/I4210089431 |
| Region | New York |
| Researchers | 5,427 |
| ROR ID | https://ror.org/0065zqt33 |
| Type | nonprofit |
| Works | 16,759 |

## University papers

Showing 12 of 33.

- [Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial](https://scholariq.org/papers/segmentectomy-versus-lobectomy-in-small-sized-peripheral-non-small-cell-lung/)
- [Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/)
- [Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer](https://scholariq.org/papers/metagenomic-and-metabolomic-analyses-reveal-distinct-stage-specific-phenotypes/)
- [Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-oesophageal-squamous/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [Teclistamab in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/teclistamab-in-relapsed-or-refractory-multiple-myeloma/)
- [Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study](https://scholariq.org/papers/bortezomib-thalidomide-and-dexamethasone-with-or-without-daratumumab-before-and/)
- [Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial](https://scholariq.org/papers/brentuximab-vedotin-with-chemotherapy-for-cd30-positive-peripheral-t-cell/)
- [Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma](https://scholariq.org/papers/talquetamab-a-t-cell-redirecting-gprc5d-bispecific-antibody-for-multiple-myeloma/)
- [Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial](https://scholariq.org/papers/mogamulizumab-versus-vorinostat-in-previously-treated-cutaneous-t-cell-lymphoma/)
- [Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2](https://scholariq.org/papers/esophageal-cancer-practice-guidelines-2017-edited-by-the-japan-esophageal/)
- [Frequent inactivation of A20 in B-cell lymphomas](https://scholariq.org/papers/frequent-inactivation-of-a20-in-b-cell-lymphomas/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Colorectal Cancer Surgical Treatments](https://scholariq.org/topics/colorectal-cancer-surgical-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.